Skip to main content
Delfa

← Trials/Trial dossier/NCT00306124

UnknownPhase 4

Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment

Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI)

Asset

Levodopa

Listed sites

1

Recruiting sites

1

Enrollment

120

estimated

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criterion

•Alzheimer's disease

Primary endpoints

•Cognitive performance•Brain activity pattern during learning under levodopa

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDLL_001 Project on Dementia/MCI
NCT IDNCT00306124

Timeline

Milestones

Study start2006-01 (month precision)
Study first posted2006-03-22estimated
Last update posted2007-10-25estimated
Study completion2008-03estimated (month precision)

Assets

Drug assets

Levodopa

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age18 Years
Maximum age90 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

for patients with dementia:

•Patients: clinical diagnosis of AD or mild cognitive impairment
•primary language German

Exclusion criteria

for healthy subjects and patients with dementia/MCI:

•Known allergy to levodopa or tetrazine
•History of medication/drug abuse
•Acute nicotine withdrawal or > 15 cigarettes per day
•> 6 cups/glasses of coffee, caffeine drinks or energy drinks per day
•> 50 grams of alcohol per day
•Severe hypertonia (systole >160 mm Hg)
•Severe arteriosclerosis
•Diabetes, asthma, or glaucoma
•Severe hearing disability
•no focal brain lesions
•Premorbid depression or psychosis
•Medication with dopamine agonists or antagonists
•Parkinsonian symptoms

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Global cognition
1

Global cognition

1 endpoint
Primary/protocol endpoint

Cognitive performance assessed by neuropsychological tests and learning paradigms under placebo and levodopa in healthy subjects and patients with dementia or Mild Cognitive Impairment.

descriptive

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Brain activity pattern during learning under levodopa as compared to placebo in healthy subjects.

descriptive

Secondary/protocol endpoint/low confidence

Long-term stability of learning performance after 1 month in healthy subjects.

descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.